Palatin Announces 1-for-50 Reverse Stock Split
Palatin Technologies (OTCQB: PTNT) has announced a 1-for-50 reverse stock split effective August 8, 2025, at 5:00 p.m. EDT. The stock will begin trading on a split-adjusted basis on August 11, 2025, under the temporary symbol PTNTD for 20 trading days.
The primary objective is to increase the per-share price to meet NYSE American's Listing Qualifications. The reverse split was approved by stockholders on July 25, 2025, with an authorized range of 1-for-50 to 1-for-100. Shareholders will receive cash for any fractional shares, and the company's new CUSIP number will be 696077 601.
Palatin Technologies (OTCQB: PTNT) ha annunciato un raggruppamento azionario inverso 1:50 con efficacia dall'8 agosto 2025 alle 17:00 EDT. Le azioni inizieranno a essere negoziate con il prezzo rettificato per il raggruppamento a partire dall'11 agosto 2025, con il simbolo temporaneo PTNTD per 20 giorni di negoziazione.
L'obiettivo principale è aumentare il prezzo per azione per soddisfare i requisiti di quotazione di NYSE American. Il raggruppamento è stato approvato dagli azionisti il 25 luglio 2025, con una fascia autorizzata da 1:50 a 1:100. Gli azionisti riceveranno un pagamento in contanti per eventuali azioni frazionarie e il nuovo numero CUSIP della società sarà 696077 601.
Palatin Technologies (OTCQB: PTNT) ha anunciado una consolidación inversa de acciones 1 por 50 con vigencia el 8 de agosto de 2025 a las 5:00 p.m. EDT. Las acciones comenzarán a cotizar ajustadas por la consolidación a partir del 11 de agosto de 2025, bajo el símbolo temporal PTNTD durante 20 días de negociación.
El objetivo principal es aumentar el precio por acción para cumplir con las calificaciones de cotización de NYSE American. La consolidación fue aprobada por los accionistas el 25 de julio de 2025, con un rango autorizado de 1 por 50 a 1 por 100. Los accionistas recibirán efectivo por cualquier acción fraccionaria y el nuevo número CUSIP de la compañía será 696077 601.
Palatin Technologies (OTCQB: PTNT)는 1대50 역분할(리버스 스플릿)을 2025년 8월 8일 오후 5시(미국 동부 일광절약시간, EDT)부로 시행한다고 발표했습니다. 주식은 2025년 8월 11일부터 분할 적용 가격으로 거래를 시작하며, 20거래일 동안 임시 심볼 PTNTD로 거래됩니다.
주당 가격을 올려 NYSE American의 상장 자격을 충족하는 것이 주된 목적입니다. 역분할은 2025년 7월 25일 주주들의 승인을 받았으며, 허용 범위는 1대50에서 1대100입니다. 주주들은 소수주에 대해 현금으로 보상받으며, 회사의 새 CUSIP 번호는 696077 601입니다.
Palatin Technologies (OTCQB: PTNT) a annoncé un regroupement d'actions inverse de 1 pour 50 prenant effet le 8 août 2025 à 17h00 EDT. L'action commencera à être négociée avec le cours ajusté du regroupement le 11 août 2025, sous le symbole temporaire PTNTD pendant 20 jours de négociation.
L'objectif principal est d'augmenter le prix par action afin de satisfaire aux exigences de cotation du NYSE American. Le regroupement a été approuvé par les actionnaires le 25 juillet 2025, avec une plage autorisée de 1 pour 50 à 1 pour 100. Les actionnaires recevront une contrepartie en espèces pour les actions fractionnaires éventuelles et le nouveau numéro CUSIP de la société sera 696077 601.
Palatin Technologies (OTCQB: PTNT) hat einen Aktienzusammenlegung im Verhältnis 1:50 (Reverse Split) mit Wirkung zum 8. August 2025 um 17:00 Uhr EDT angekündigt. Die Aktie wird ab dem 11. August 2025 kursbereinigt gehandelt und für 20 Handelstage unter dem vorübergehenden Symbol PTNTD geführt.
Hauptziel ist die Erhöhung des Kurswerts je Aktie, um die Notierungsanforderungen der NYSE American zu erfüllen. Der Reverse-Split wurde von den Aktionären am 25. Juli 2025 genehmigt, mit einem autorisierten Bereich von 1:50 bis 1:100. Aktionäre erhalten Bargeld für etwaige Bruchstücke von Aktien, und die neue CUSIP-Nummer des Unternehmens lautet 696077 601.
- Potential uplisting to NYSE American market from OTCQB
- Higher stock price may attract institutional investors and improve trading visibility
- Significant share consolidation indicates previous price deterioration
- No fundamental change in company value or market capitalization
One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to satisfy compliance with the NYSE American's Listing Qualifications related to the low selling price of the Company's common shares.
At the annual meeting of stockholders held on July 25, 2025, the Company's stockholders approved an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio of 1-for-50 to 1-for-100, with such ratio to be determined by the Company's Board of Directors.
As of the Effective Time, every 50 shares of the Company's issued and outstanding Common Stock will be combined into one share of Common Stock. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. The par value and other terms of the Common Stock will not be affected by the Reverse Stock Split. The Company's post-Reverse Stock Split Common Stock CUSIP number will be 696077 601.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to advance its innovative melanocortin agonists through development and partner with leading pharmaceutical companies to accelerate progress, expand patient access, and maximize commercial success. For additional information, visit www.Palatin.com and follow Palatin on X (formerly Twitter) at @PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about Palatin products in development, clinical trial results, potential actions by regulatory agencies, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.
Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-announces-1-for-50-reverse-stock-split-302524862.html
SOURCE Palatin Technologies, Inc.
FAQ
What is the ratio of Palatin Technologies' (PTNT) reverse stock split?
When will Palatin's (PTNT) reverse stock split take effect?
Why is Palatin Technologies (PTNT) doing a reverse stock split?
What will happen to Palatin's stock symbol after the reverse split?
What happens to fractional shares in Palatin's reverse stock split?
